Medtronic is trading at $81.97 (5.5% down) after a notable after-hours decline, diverging from the broader market's positive performance.
- The move appears driven by low-liquidity extended-hours trading dynamics rather than a clearly identified company catalyst.
- There are no fresh earnings, FDA announcements, or M&A headlines specifically tied to the company in the post-close window.